iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2263

Identifiers

  • Canonical SMILES: 
    CC=CCn1cc(-c2cccc(c2)C(=O)N(C)C)c2cc[nH]c2c1=O
  • IUPAC name: 
    3-[6-(but-2-en-1-yl)-7-oxo-1H,6H,7H-pyrrolo[2,3-c]pyridin-4-yl]-N,N-dimethylbenzamide
  • InChi: 
    InChI=1S/C20H21N3O2/c1-4-5-11-23-13-17(16-9-10-21-18(16)20(23)25)14-7-6-8-15(12-14)19(24)22(2)3/h4-10,12-13,21H,11H2,1-3H3
  • InChiKey: 
    RJEMCUZKQLRUIS-UHFFFAOYSA-N

External links


145767868
69G

External search

Bibliography (1)

Publication Name
Crawford Terry D., Tsui Vickie, Flynn E. Megan, Wang Shumei, Taylor Alexander M., Côté Alexandre, Audia James E., Beresini Maureen H., Burdick Daniel J., Cummings Richard, Dakin Les A., Duplessis Martin, Good Andrew C., Hewitt Michael C., Huang Hon-Ren, Jayaram Hariharan, Kiefer James R., Jiang Ying, Murray Jeremy, Nasveschuk Christopher G., Pardo Eneida, Poy Florence, Romero F. Anthony, Tang Yong, Wang Jian, Xu Zhaowu, Zawadzke Laura E., Zhu Xiaoyu, Albrecht Brian K., Magnuson Steven R., Bellon Steve, Cochran Andrea G.. . Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains Journal of Medicinal Chemistry. Compound 4

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
5 0 0 0

Targets

PPI family Best activity Diseases MMoA
Bromodomain / Histone 6.80 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 335.16 g/mol
HBA 5
HBD 1
HBA + HBD 6
AlogP 2.40
TPSA 56.41
RB 4
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 5 0 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b00264 Compound 4 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET BRD4(1) pIC50 (half maximal inhibitory concentration, -log10) 6.34
10.1021/acs.jmedchem.6b00264 Compound 4 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET BRD4(2) pIC50 (half maximal inhibitory concentration, -log10) 5.85
10.1021/acs.jmedchem.6b00264 Compound 4 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET BRD9 pIC50 (half maximal inhibitory concentration, -log10) 6.80
10.1021/acs.jmedchem.6b00264 Compound 4 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET TAF1(1) pIC50 (half maximal inhibitory concentration, -log10) 6.39
10.1021/acs.jmedchem.6b00264 Compound 4 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET CECR2 pIC50 (half maximal inhibitory concentration, -log10) 5.24
Ta Structure Name Drugbank ID
0.4767 Ozenoxacin DB12924
0.4725 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide DB08583
0.4706 Dactolisib DB11651
0.4663 N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide DB06834
0.4620 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one DB07528
0.4615 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE DB08350
0.4557 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine DB08398
0.4521 4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione DB07257
0.4444 Perampanel DB08883
0.4444 LY-3023414 DB12167
0.4431 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE DB07025
0.4372 Tazemetostat DB12887
0.4364 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol DB06898
0.4350 3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID DB07265
0.4342 Rosoxacin DB00817